Nick George has been developing and evaluating biologics-based patent portfolios for more than 25 years. He has devised worldwide patent prosecution strategies and evaluated portfolios involving antibodies, antibody drug conjugates, immuno-oncology, cellular therapeutics (including stem cell, natural killer cell, CAR-T, and induced pluripotent stem cell [iPS] therapeutics), gene therapies, oncolytic viruses, CRISPR (gene editing), antisense and other RNA therapeutics, peptide therapeutics, and companion diagnostics and enzyme replacements, among others.
Nick has developed patent strategies for such marketed products as Fuzeon®, Kynamro®, Fabrazyme®, Syvek®, and Talymed® and for such biologics drug candidates as Celgene and Celularity's cellular therapeutics and Celldex Therapeutics' ErbB3 and KIT antibody clinical candidates. He also has developed patent strategies for such diagnostic products as Phenosense™, GeneSeq™, Replication Capacity™, and the companion diagnostic, Trofile™ (Monogram, now LabCorp).
Nick holds a Ph.D. in genetics from the University of California, Berkeley (1990). Following a postdoctoral fellowship at Columbia University, he joined the legal intern program at his previous firm, during which time he also attended the evening program of Fordham University School of Law.
- Fordham University (J.D. 1997); Columbia University (Postdoctoral Fellow, 1990-1992); University of California, Berkeley (Ph.D. in Genetics 1990); University of Dallas (B.S. in Biology cum laude 1984)
- New York and registered to practice before the United States Patent and Trademark Office